Abstract
Basic sample size and power formulae for cost-effectiveness analysis have been established in the literature. These formulae are reviewed and the similarities and differences between sample size and power for cost-effectiveness analysis and for the analysis of other continuous variables such as changes in blood pressure or weight are described. The types of sample size and power tables that are commonly calculated for cost-effectiveness analysis are also described and the impact of varying the assumed parameter values on the resulting sample size and power estimates is discussed. Finally, the way in which the data for these calculations may be derived are discussed.
Similar content being viewed by others
References
Glick HA, Doshi JA, Sonnad SS, et al. Economic evaluation in clinical trials. Oxford: Oxford University Press, 2007
Glick HA. Sample size and power for cost-effectiveness analysis (part 2): the effect of maximum willingness to pay. Pharmacoeconomics. In press
Willan AR. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. Control Clin Trials 2001; 22: 228–37
Fleiss JL. The design and analysis of clinical experiments. New York: Wiley Interscience, 1986: 369
Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68–80
Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003; 163: 41
Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437–52
Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518–28
Cressy D. Life in the balance. Nature 2009; 461: 336–9
Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397–406
O’Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decis Making 2001; 21: 219–30
McIntosh MW, Ramsey SD, Berry K, et al. Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes. Health Econ 2001; 10: 53–66
Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost effectiveness ratios: a comparison of four methods. Health Econ 1997; 6: 243–52
Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making 1998; 18: S81–92
Briggs A, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions (Working Paper Series in Economics and Finance No. 234). Stockholm: Stockholm School of Economics, 1998
Laska EM, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Med Decis Making 1999; 19: 339–43
Willan AR, O’Brien BJ. Sample sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 1999; 8: 203–11
Gardiner JC, Huebner M, Jetton J, et al. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Econ 2000; 9: 227–34
Koerkamp BG, Spronk S, Stijnen T, et al. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication. Value Health 2010; 13: 242–50
Gafni A, Walter SD, Birch S, et al. An opportunity cost approach to sample size calculation in cost-effectiveness analysis. Health Econ 2008; 17: 99–107
Al MJ, Van Hout BA, Michel BC, et al. Sample size calculation in economic evaluations. Health Econ 1998; 7: 327–35
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
Acknowledgements
This article was funded in part by the Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center.
The author has no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Glick, H.A. Sample Size and Power for Cost-Effectiveness Analysis (Part 1). Pharmacoeconomics 29, 189–198 (2011). https://doi.org/10.2165/11585070-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11585070-000000000-00000